



The selection of efficient sgRNAs for *CRISPR-Cas9* genome editing of potato (*Solanum tuberosum* L.) aimed to obtain the cultivars with low-amylose starch properties

Sergeeva E.M.**, *Larichev K.T.*, *Bragina M.K.*, *Salina E.A.*, *Kochetov A.V.

Kurchatov Genomics Center, Institute of Cytology and Genetics SB RAS, Lavrentiev ave., 10, 630090, Novosibirsk, Russia;

*e-mail: sergeeva@bionet.nsc.ru

Potato (*Solanum tuberosum* L.) ($2n = 4x = 48$) is an important starch producing agricultural plant. Starch is the main storage carbohydrate widely used for industrial and nutritional needs. The two main components of starch are polysaccharides amylose and amylopectin, which account for approximately 20-25 and 75-80 % of native potato starch, respectively. The starch functional properties (swelling power, viscosity, gelatinization) are mainly defined by the ratio of amylose and amylopectin. The low-amylose starches known as “waxy” and have high gelatinization and pasting properties, whereby are widely used in food and non-food industry. The *GBSS1* gene is known to be responsible for amylose biosynthesis in potato tubers. There are several studies devoted to CRISPR/Cas9 knockout of *GBSS1* gene in potato cultivars Kuras, Sayaka, Desiree, Wotan, resulted in successful production of low- and no amylose transformants [1-4].

The aim of the study is development of Russian potato varieties with low- or no-amylose starch properties using the *CRISPR-Cas9* genome editing.

Methods and Results

The cultivars of choice for editing are popular Russian varieties **Nevskiy** and **Udacha**, which have good *in vitro* regeneration ability and good crop yield.

We used Illumina genomic sequencing data for **Nevskiy** and **Udacha** (obtained on NextSeq550 at the ICG SB RAS Core Genome Facility). The Illumina reads were aligned to the *GBSS1* from PGSC reference genomic sequence. Therefore we obtained the *GBSS1* locus consensus sequences for our cultivars.

```

1041 1050 1060 1070 1080 1090 1100 1110 1120 1130 1140 1150 1160 1170
R23741_(GeneBank) TGTTCATATCTCATCTCATCTATCTGATTTGATTCCTTGCCTACTGTAACGGTGAATAAGTGAATGCTTCCCTTTCTCTCAGAAATCAATTTCTGTTT-TGTTTT
X58453.1_P65C TGTTCATATCTCATCTCATCTATCTGATTTGATTCCTTGCCTACTGTAACGGTGAATAAGTGAATGCTTCCCTTTCTCTCAGAAATCAATTTCTGTTT-TGTTTT
X58453.1_consensus_N TGTTCATATCTCATCTCATCTATCTGATTTGATTCCTTGCCTACTGTAACGGTGAATAAGTGAATGCTTCCCTTTCTCTCAGAAATCAATTTCTGTTT-TGTTTT
X58453.1_consensus_U AGAACCAGAGGGGCCCATTCAGAGCCAGTGGAG-TCCAGCCCTGAATCAGC-----AAGAGAGGGG--CCA-----TAAATAC16TGGATGACATTCCCTTCCCTCTCT
Consensus TGTTCATATCTCATCTCATCTATCTGATTTGATTCCTTGCCTACTGTAACGGTGAATAAGTGAATGCTTCCCTTTCTCTCAGAAATCAATTTCTGTTT-TGTTTT
1171 1180 1190 1200 1210 1220 1230 1240 1250 1260 1270 1280 1290 1300
R23741_(GeneBank) TGTTCATCTGTAGCTTATCTCTGGTAGATCCCTTTTTGTAGCCACACATCAGATGCGAGCATCAGCTTCACACCCTTTGTGTCAGAGGCCAARCTTCACTAGACACCAATCACCCTTGT
X58453.1_P65C TGTTCATCTGTAGCTT-----GGTAGATCCCTTTTTGTAGCCACACATCAGATGCGAGCATCAGCTTCACACCCTTTGTGTCAGAGGCCAARCTTCACTAGACACCAATCACCCTTGT
X58453.1_consensus_N TGTTCATCTGTAGCTT-----GGTAGATCCCTTTTTGTAGCCACACATCAGATGCGAGCATCAGCTTCACACCCTTTGTGTCAGAGGCCAARCTTCACTAGACACCAATCACCCTTGT
X58453.1_consensus_U TCTTCTCTTCTCTCT-----CTTCTCTTTTTGTAGCCACACATCAGATGCGAGCATCAGCTTCACACCCTTTGTGTCAGAGGCCAARCTTCACTAGACACCAATCACCCTTGT
Consensus TGTTCATCTGTAGCTT-----GGTAGATCCCTTTTTGTAGCCACACATCAGATGCGAGCATCAGCTTCACACCCTTTGTGTCAGAGGCCAARCTTCACTAGACACCAATCACCCTTGT


```

```

4161 4170 4180 4190 4200 4210 4220 4230 4240 4250 4260 4270 4280 4290
R23741_(GeneBank) TCACCTTGCCRAGGAARATGAGCCACTCCCTAATGAGCTTTGGTTATCCTGTTTCACCAATAGATCATTAGCRAACGATTTACTAGCGAATGTAGAACCTTATTGGGGCTCARTATC
X58453.1_P65C TCACCTTGCCRAGGAARATGAGCCACTCCCTAATGAGCTTTGGTTATCCTGTTTCACCAATAGATCATTAGCRAACGATTTACTAGCGAATGTAGAACCTTATTGGGGCTCARTATC
X58453.1_consensus_N TCACCTTGCCRAGGAARATGAGCCACTCCCTAATGAGCTTTGGTTATCCTGTTTCACCAATAGATCATTAGCRAACGATTTACTAGCGAATGTAGAACCTTATTGGGGCTCARTATC
X58453.1_consensus_U TCACCTTGCCRAGGAARATGAGCCACTCCCTAATGAGCTTTGGTTATCCTGTTTCACCAATAGATCATTAGCRAACGATTTACTAGCGAATGTAGAACCTTATTGGGGCTCARTATC
Consensus TCACCTTGCCRAGGAARATGAGCCACTCCCTAATGAGCTTTGGTTATCCTGTTTCACCAATAGATCATTAGCRAACGATTTACTAGCGAATGTAGAACCTTATTGGGGCTCARTATC
4291 4300 4310 4320 4330 4340 4350 4360 4370 4380 4390 4400 4410 4420
R23741_(GeneBank) TACAAATGATGGTTTTGCTGGGGAGCAGCATATAGGCTGTAARATCCTGGTAAATGTTTTGAGGTAGGGCTATTAGGGTGGTGGATCAAGTCAATAGAAATAGTTATTACTACG
X58453.1_P65C TACAAATGATGGTTTTGCTGGGGAGCAGCATATAGGCTGTAARATCCTGGTAAATGTTTTGAGGTAGGGCTATTAGGGTGGTGGATCAAGTCAATAGAAATAGTTATTACTACG
X58453.1_consensus_N TACAAATGATGGTTTTGCTGGGGAGCAGCATATAGGCTGTAARATCCTGGTAAATGTTTTGAGGTAGGGCTATTAGGGTGGTGGATCAAGTCAATAGAAATAGTTATTACTACG
X58453.1_consensus_U TACAAATGATGGTTTTGCTGGGGAGCAGCATATAGGCTGTAARATCCTGGTAAATGTTTTGAGGTAGGGCTATTAGGGTGGTGGATCAAGTCAATAGAAATAGTTATTACTACG
Consensus TACAAATGATGGTTTTGCTGGGGAGCAGCATATAGGCTGTAARATCCTGGTAAATGTTTTGAGGTAGGGCTATTAGGGTGGTGGATCAAGTCAATAGAAATAGTTATTACTACG

```


The 6 specific pairs of PCR primers were designed to *GBSS1* for **Nevskiy** and **Udacha** in order to amplify the target genomic sequences for *in vitro* CRISPR/Cas9 testing.



Design of sgRNA The obtained *GBSS1* consensus gene sequences were analyzed with CRISPOR, CRISPRdirect, CRISPR-P programmes to pick the candidate sgRNAs. From 109 total output oligos six were selected based on criteria of predicted specificity and secondary structure. The six selected sgRNAs are targeted to *GBSS1* exons 1, 2 and 10.


sgRNA	Exon number	Number of target sites		
		20 mer	12 mer	8 mer
Sg_RNA_1	1	1	1	204
Sg_RNA_2	1	1	2	469
Sg_RNA_3*	1	1	5	967
Sg_RNA_4	1	1	1	557
Sg_RNA_6	2	1	1	97
Sg_RNA_7	10	1	1	539

* The sgRNA 3 variant was already successfully used by Johansen et al., 2019 [3]



Verification of the secondary structure of selected sgRNAs

The sgRNA positions on *GBSS1* sequence



In vitro testing of sgRNA

The next step was the synthesis of designed sgRNAs and *in vitro* pre-validation as part of Cas9 ribonucleoprotein (RNP) complex.


Sg_RNA_3 and Sg_RNA_6 was synthesized with the aid of Precision gRNA Synthesis Kit (Invitrogen).

Sg_RNA_3 was successfully used to cleave the PCR-produced *GBSS1* sequences of Nevskiy and Udacha.

The remaining sgRNAs are ready for cloning to pUC57-sgRNA expression vector and will be *in vitro* tested in the near future.

Conclusion We designed 6 sgRNAs targeted to *GBSS1* gene of popular Russian potato cultivars Nevskiy and Udacha, one of sgRNAs was *in vitro* tested and demonstrated efficacy to cleave PCR-produced *GBSS1*. Further the *in vitro* effective sgRNAs will be used for DNA-free (RNP) biolistic transformation of potato protoplasts and explants.

In vitro testing of Sg_RNA_3



References

- 1) Andersson et al., Plant Cell Reports, 2017, v 36, p 117–128
- 2) Kusano et al., Scientific Reports, 2018, v 8, Article number: 13753
- 3) Johansen et al., Scientific Reports, 2019, v 9, Article number: 17715
- 4) Veillet et al., Plant Cell Reports, 2019, v 38, p 1065–1080

This work was done within the framework of State Assignment Kurchatov Genomic Center of ICG SB RAS (075-15-2019-1662).